Targeted therapy for neuropsychiatric disorders requires selective modulation of dysfunctional neuronal pathways. Receptors relevant to CNS disorders typically have associated proteins discretely expressed in specific neuronal pathways; these accessory proteins provide a new dimension for drug discovery. Recent studies show that targeting a TARP auxiliary subunit of AMPA receptors selectively modulates neuronal excitability in specific forebrain pathways relevant to epilepsy. Other medicinally important ion channels, gated by glutamate, g-aminobutyric acid (GABA), and acetylcholine, also have associated proteins, which may be druggable. This emerging pharmacology of receptor-associated proteins provides a new approach for improving drug efficacy while mitigating side effects.
Targeted therapy for neuropsychiatric disorders requires selective modulation of dysfunctional neuronal pathways. Receptors relevant to CNS disorders typically have associated proteins discretely expressed in specific neuronal pathways; these accessory proteins provide a new dimension for drug discovery. Recent studies show that targeting a TARP auxiliary subunit of AMPA receptors selectively modulates neuronal excitability in specific forebrain pathways relevant to epilepsy. Other medicinally important ion channels, gated by glutamate, g-aminobutyric acid (GABA), and acetylcholine, also have associated proteins, which may be druggable. This emerging pharmacology of receptor-associated proteins provides a new approach for improving drug efficacy while mitigating side effects.
Discovery and development of new medicines to treat neuropsychiatric disorders are complex, lengthy, expensive, and risky. Recent data indicate that it requires on average 11-13 years to progress a project from target identification to drug approval (Evens, 2016; Lamberti and Getz, 2015) . This involves 3-5 years in preclinical discovery and 5-10 years in clinical development. Because the pharmaceutical industry focuses on more complex diseases, the costs to discover and develop new medicines have increased far faster than inflation, and recent estimates suggest that each new molecular entity costs $2.6 billion, up more than 300% from costs in the 1990s (Evens, 2016; Lamberti and Getz, 2015) . A major contributor to expense is the high failure rate; less than 10% of drug discovery programs ultimately result in clinically approved medicines. The success rates in neurology and psychiatry are even lower (Hay et al., 2014) .
Many factors contribute to attrition in drug discovery, and the relative importance of different failure modes has evolved with time. Issues related to drug exposure and toxicology have historically been the major reasons for termination of drug development programs (Kola and Landis, 2004) . As preclinical models for pharmacokinetics, metabolism, and safety have improved, the attrition attributed to these domains has decreased (Waring et al., 2015) . The major cause for failure now is lack of efficacy in phase II (Waring et al., 2015) , when experimental medicines are rigorously tested for clinical benefit in diseased patients. A prescient sensitivity analysis argued that improved success in phase II would provide the greatest benefit for pharmaceutical research and development (R&D) productivity (Paul et al., 2010) .
Choosing the correct targets-ones that can yield efficacy in phase II-therefore represents a supreme challenge for new pharmaceuticals. Selecting targets in neuropharmacology may follow a variety of strategies. Targets may be linked to a specific disease by genetic, pathological, behavioral, or pathways analyses. After a target is prioritized, a pharmacological modulator must be discovered. This typically involves expressing the receptor, channel, or enzyme of interest in a simplified cell line and screening a large and diverse collection of molecules. Although facile, this reductionist approach does not incorporate the broader protein complex for the target and can miss physiological features and pharmacological sites. Here we will outline a richer strategy for targeting receptor-associated proteins. We will first provide some historical examples of drugs that target receptor auxiliary subunits.
Pharmacological Discovery of Receptor-Associated Proteins
Although target-based high-throughput screening is the starting point for most modern drug discovery programs, some drugs continue to be discovered through ''phenotypic screens '' (Swinney and Anthony, 2011) . This strategically distinct approach also employs chemical libraries but evaluates compound effects on cellular or even whole-animal readouts. Because phenotypic screens are unbiased, they provide valuable insights regarding fruitful sources for drug discovery targets. Important for this review is that many drugs discovered in phenotypic screens target multi-subunit complexes, some of which are heteromeric ion channels. Table 1 displays several examples of medicines and experimental therapeutic agents that modulate protein complexes.
The blockbuster drug gabapentin is a constrained analog of the inhibitory neurotransmitter g-aminobutyric acid (GABA) and was originally prioritized based on its ability to block seizures in animals (Satzinger, 1994) . Subsequent biochemical studies showed that gabapentin's actions are due to its nanomolar affinity for voltage-gated calcium channels. Importantly, gabapentin does not bind to the pore-forming principal subunit of the calcium channel but, instead, to the a2d auxiliary subunit (Field et al., 2006; Suman-Chauhan et al., 1993) . As another example, sulfonylureas, among the most widely prescribed class of medicines for type II diabetes, enhance insulin secretion by blocking an inwardly rectifying potassium channel on pancreatic b cells (Ashcroft, 2005) . Again, these drugs do not directly interact with the Kir ion channel protein and, instead, bind to an auxiliary subunit, the sulfonylurea receptor (Aguilar-Bryan et al., 1995) .
Although drugs targeting receptor-associated proteins have historically emerged as part of phenotypic screens, recent advances now enable intentional pursuit of this approach. Because targeting receptor-associated proteins can provide a more versatile and selective pharmacology, this strategy has recently garnered great interest. Also, rapid advances in structural biology of transmembrane proteins, especially cryoelectron microscopy (cryo-EM), enable structure-guided medicinal chemistry of macromolecular receptor targets. We will first review means for identifying receptor-associated proteins complexes and for translating these discoveries into drug-hunting programs. We will then highlight emerging drug discovery efforts targeting receptor-associated proteins and describe future opportunities for this strategy.
Strategies for Identification of Receptor-Associated Proteins
Several disparate approaches have identified receptor-associated proteins (Figure 1 ). Historically, they have been discovered during biochemical and pharmacological investigation of specific receptors or pathways ( Figures 1A and 1B) . Biochemical purifications of the voltage-gated calcium channel identified a2d, b, and g auxiliary subunits as components of that receptor (Arikkath and Campbell, 2003; Catterall, 2000) . The ''sulfonylurea receptor'' subunit of the inwardly rectifying potassium channel of b islet cells mentioned above was found while determining the mechanism of action of sulfonylureas. Molecular characterization of a receptor has sometimes revealed an unexpected auxiliary component. Expression cloning of the calcitonin gene-related peptide (CGRP) receptor demonstrated that it requires both a classical seven-pass transmembrane component and a unique receptor activity-modifying protein 1 (RAMP1) auxiliary subunit (McLatchie et al., 1998) .
Receptor-associated proteins have also emerged unexpectedly in genetic mapping studies ( Figure 1C ). Such studies of stargazer mice, which suffer absence epilepsy and cerebellar ataxia (Noebels et al., 1990) , identified mutations in the four-pass transmembrane protein stargazin (Letts et al., 1998) . Subsequent physiological studies (Chen et al., 2000; Hashimoto et al., 1999) determined that stargazin is the prototypical transmembrane a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)-associated protein (TARP), a family of AMPAR auxiliary subunits (Tomita et al., 2003; Vandenberghe et al., 2005) . Drug discovery programs focused on TARP subunits are described in detail below.
The suppressor of lurcher-1 (SOL-1) subunit of worm glutamate receptors was discovered in a clever forward genetic screen in C. elegans worms ( Figure 1C ) in which an constitutively active glutamate receptor mutant resembling the toxic lurcher allele (Zuo et al., 1997) was used to identify glutamate receptor modifiers (Zheng et al., 2004) . Subsequent analyses showed that ionotropic glutamate receptors in worms require both SOL-1 and TARP auxiliary subunits .
Protein interaction screening methodologies such as the yeast two-hybrid system have also been used extensively to search for receptor-associated proteins. Because these techniques cannot routinely detect transmembrane domain interactions, the yeast two-hybrid system primarily identifies structural components that link receptors to the neuronal cytoskeleton (Anggono and Huganir, 2012; Kim and Sheng, 2004) .
The sequencing of the human genome has enabled systematic screening strategies to identify receptor-associated proteins. Loss-of-function screens can use a variety of approaches; the most effective ones now utilize RNAi (Mohr et al., 2014) or CRISPR-Cas9 (Shalem et al., 2015) . An important application used RNAi screening to identify Orai1 as the plasma membrane pore interacting with the endoplasmic reticulum (ER) calcium sensor STIM1, which mediates a Ca 2+ releaseactivated (CRAC) channel Prakriya et al., 2006) . Together, these proteins reconstitute CRAC, which plays a central role in cell biology and human disease (Lacruz and Feske, 2015) . Using multiple screening strategies can be especially effective for gene discovery. In the case of CRAC channels, linkage analysis in patients with severe combined immunodeficiency, which was known to reflect deficient CRAC activity in lymphocytes, combined with RNAi screening for CRAC activity in a Drosophila cell line, converged on Orai1 . A new and complementary approach uses cDNA overexpression to identify receptor-associated proteins ( Figure 1D ). This was recently achieved (Gu et al., 2016) for the a7 nicotinic acetylcholine receptor (nAChR), which does not assemble into its homopentameric structure and does not form a functional channel in non-neuronal cell lines (Lindstrom, 1997) . Co-transfecting a7 with a genomic library encoding all human proteins containing a transmembrane domain identified NACHO, a novel four pass transmembrane protein that is necessary for assembly of a7 and certain other neuronal nAChRs (Gu et al., 2016; Matta et al., 2017) . Because of their tremendous power, genome-wide RNAi knockdown and cDNA overexpression approaches will increasingly be used to identify systematically receptor-associated components. Such reconstitution of native receptors in cell lines provides a key starting point for drug discovery programs. Using the framework outlined above, molecules have been discovered that specifically modulate an auxiliary subunit of AMPA-type glutamate receptors, and this will be reviewed in detail.
Neuropharmacology of AMPARS
Glutamate, the main fast excitatory neurotransmitter in the CNS, acts primarily on three subtypes of ionotropic receptors, named according to their sensitivity to exogenous agonists: AMPA, N-methyl-D-aspartate (NMDA), and kainate. As the predominant determinants of excitatory synaptic strength in central neurons and circuits, AMPARs are critically involved in most brain functions. Thus, they represent attractive pharmacological targets for neuropsychiatric disorders characterized by abnormal circuit-or system-level activity. However, general inhibition of AMPARs globally perturbs brain physiology and causes doselimiting side effects, including dizziness, ataxia, and sedation (Rogawski, 2011) . Four genes encode the pore-forming subunits of AMPARs (GluA1-4) (Hollmann and Heinemann, 1994) ; AMPAR expression, assembly, trafficking, synaptic localization, and biophysics have been reviewed in detail (Mayer, 2016) . Numerous drug discovery efforts have produced a rich pharmacopeia comprising a wide variety of agonists, antagonists, and modulators acting at five distinct sites on the GluA pore-forming subunits (Traynelis et al., 2010;  Figure 3A ). Here we focus on novel pharmacologies arising from AMPAR-associated proteins.
TARP-Selective Modulators
The first set of integral membrane proteins discovered to bind to AMPARs are the TARPs (Chen et al., 2000; Hashimoto et al., 1999; Tomita et al., 2003) . This family, comprising the genes CACNG2, 3, 4, and 8 (type 1 TARPs) and CACNG5 and 7 (type 2 TARPs), were named based on homology with CACNG1, the gamma subunit of voltage-gated calcium channels (Letts et al., 1998) . TARPs were subsequently found to be essential for neuronal AMPAR function in neurons (Chen et al., 2000; Hashimoto et al., 1999) . TARPs enhance trafficking of AMPARs to the plasma membrane and to synapses, and TARPs differentially modulate AMPAR gating (Cho et al., 2007; Jackson and Nicoll, 2011) . TARPs also alter the pharmacology of AMPARs. Type 1 TARPs increase the potency of the positive allosteric modulator cyclothiazide (Tomita et al., 2006) , convert certain competitive antagonists into partial agonists (Menuz et al., 2007) , and increase the efficacy of the partial agonist kainate (Tomita et al., 2005) .
The motivation for TARP-specific modulators derived from their anatomical segregation in discrete brain regions. In particular, TARP g-8 predominates in the hippocampus and has minimal expression in the hindbrain or midbrain (Tomita et al., 2003) . Therefore, an inhibitor of TARP g-8 could have therapeutic utility in disease states characterized by hippocampal hyperexcitability, such as temporal lobe epilepsy, anxiety disorders, bipolar depression, and prodromal schizophrenia. Furthermore, blocking only TARP g-8-containing receptors may avoid the motor side effects observed with pan-AMPAR inhibitors such as perampanel (Russo et al., 2012) . Directed medicinal chemistry efforts by researchers at Janssen and at Lilly produced negative modulators of AMPARs with exquisite selectivity for TARP g-8 ( (D) Genomic cloning strategies, either using RNAi or cDNA overexpression (shown here), can isolate receptor-associated proteins (e.g., NACHO for a7 nAChR).
These chemically distinct g-8 modulators, whose structures are shown in Figure 2A , share several pharmacological features (Kato et al., 2016; Maher et al., 2016) . They negatively modulate the peak and steady-state currents evoked by glutamate in recombinant and neuronal AMPARs containing TARP g-8 ( Figure 2B ). They are 100-to more than 1,000-fold selective for g-8-containing receptors compared with receptors containing other TARPs or with ''TARP-less'' AMPARs ( Figure 2C ). This specificity applies to all homomeric and heteromeric GluA combinations with g-8 (Kato et al., 2016; Maher et al., 2016 Figures 2D and 2E ). Site-directed mutagenesis studies (Kato et al., 2016; Maher et al., 2016) demonstrate that the TARP selectivity for these molecules is governed entirely by two amino acids unique to TARP g-8: G210 and V177 (amino acid numbering based on human CACNG8, UniProt: Q8WXS5). These critical glycine and valine residues are conserved in g-8 across species, as are the corresponding alanine and isoleucine residues in all other type 1 TARPs ( Figure 2F ). Potency of modulation by the TARP g-8-selective compounds is abolished by mutating these two residues in g-8 to those in the other type I TARPs, whereas TARPs g-3 and g-4 can be rendered sensitive simply by mutating these two residues to those found in g-8 (Kato et al., 2016; Maher et al., 2016) .
The binding site for TARP g-8-molecules has not been definitively determined. Recently, the first high-resolution cryo-EM structures of AMPARs in complex with TARPs have been reported (Twomey et al., 2016; Zhao et al., 2016) . Figure 3A shows the structure of g-2 in complex with GluA2 as determined by cryo-EM (adapted from Zhao et al., 2016; PDB: 5KK2) , with the two above-mentioned residues determining g-8 selectivity highlighted in yellow. Additional residues found to alter the potency, but not the g-8 selectivity, of JNJ-55511118 (N173, G209, and F213) are also highlighted in yellow. These residues cluster within a small region and delineate a potential binding pocket along the third and fourth transmembrane domains of the TARP, straddling the M1 domain GluA.
We modified the cryo-EM structure by adding the missing side chains using Prime (Schrö dinger Release 2016-3) after converting the selectivity-determining residues to their TARP g-8 form. We used SiteMap to search for plausible small-molecule binding sites on the entire protein and were pleased to see that our hypothesized pocket had one of the highest scores. A model of JNJ-55511118 minimized in this site is shown in Figures 3B  and 3C . The trifluoromethoxy moiety in JNJ-55511118 is proximal to the first g-8 selectivity residue (V177 in TM3), whereas the chloro in JNJ-55511118 points toward the second g-8 selectivity residue (G210 in TM4). Importantly, both selectivitydetermining changes from g-8 to g-4 (V177I and G210A) involve addition of a single methyl group. The tight fit in this region suggests that the larger amino acids in TARPs other than g-8 sterically inhibit drug binding.
This molecular modeling points to additional interactions that may contribute to the binding pocket. The imidazolidone in JNJ-55511118 is surrounded by the Y180 residue in TM3 and the Y202/Y207 residues in TM4, with a predicted hydrogen bond to the hydroxyl of Y207. In addition, the M1 domain of the GluA subunit lies within a groove formed by TM3 and TM4 of TARP. Several residues along M1 lie near the putative binding pocket, including D533, P534, E538, M541, C542, F545, and G549 (for clarity, the numbering has been converted to the corresponding residues of human GluA1, UniProt: P42261). Two other residues (F810 and G815) from the M4 transmembrane domain of an adjacent GluA subunit may also contribute.
A molecular modeling strategy based on the crystal structure of mouse claudin-19 was recently used to create a homology model for TARP-g8 and to approximate the binding pocket of LY3130481 (Lee et al., 2017 ). The resulting model implies a close interaction with G210 of TARP-g8 and interaction with the backbone of the V177 through multiple water molecules. This model also predicts interactions with E217 and with Y207, which was shown to slow binding and unbinding kinetics of the modulator (Lee et al., 2017) . Future mutagenesis studies of both g-8 and GluA, as well as cryo-EM or the crystal structures of modulators bound to the AMPAR/TARP complexes, will help refine models of the binding pocket and the structure-function relationships involved in TARP modification of the AMPAR. They may also be useful for rational drug design of novel TARP-selective modulators.
Mechanism for TARP g-8-Selective Negative Allosteric Modulators The mechanism for modulation by g-8-selective modulators remains uncertain. These compounds show near-complete block of steady-state currents, yet they block only about 50% of peak currents or synaptic currents from g-8-containing receptors (Kato et al., 2016; Maher et al., 2016) . The residual current that remains after block shows that these compounds partially reverse some but not all influences of g-8. Specifically, the residual current shows deactivation and desensitization kinetics intermediate between those in TARP-less AMPARs and those containing g-8 (Kato et al., 2016; Maher et al., 2016) . On the other hand, the residual current shows the high kainate/glutamate current ratio and the accelerated kinetics for recovery from desensitization characteristic of receptors containing TARPs. Furthermore, biochemical studies show that LY3130481 does not dissociate g-8 from GluA (Kato et al., 2016) .
One hypothesis regarding the mechanism is that the antagonist binding site is physically near or coupled to a critical modulatory point of contact between the TARP and the GluA subunits. Mutagenesis studies originally established that modulation of AMPAR gating and kainate efficacy is mediated by the TARP first extracellular loop (Tomita et al., 2005) and its interaction with the GluA ligand-binding domain (LBD) . X-ray crystallography studies of the clamshell-like ligand binding domain of GluA subunits show that the efficacy of AMPAR agonists correlates with the degree of agonist-induced domain closure (Armstrong et al., 2003) . Recently, high-resolution structures of AMPARs both in the absence and presence of TARP g-2 provided ground-breaking insights (Twomey et al., 2016; Zhao et al., 2016) . Molecular modeling based on these structures suggests substantial interaction between the acidic residues in extracellular domains of TARP with basic residues at the lower edge of the LBD of GluA. Indeed, mutagenesis studies identified a conserved lysine-glycine-lysine motif (KGK) at the lower edge of the LBD that is required for TARP-mediated effects on gating, but not kainate efficacy (Dawe et al., 2016) , which generally resembles the effects of g-8 antagonists. Although this KGK motif is spatially removed from the proposed g-8 binding site (Figure 3) , TARPs coordinate AMPAR gating through a network of distinct structural pathways (Dawe et al., 2016) . Dissecting these mech- Also, future AMPAR atomic structures containing g-8-modulators should help to resolve these mechanistic questions.
In addition to the TARPs, proteomics efforts have identified several additional classes of proteins as auxiliary proteins of AMPARs (Schwenk et al., 2009) . Best studied are the tightly adherent inner core auxiliary subunits, including TARPs, cornichons (CNIH-2/3), and GSG1-L, as well as the more loosely associated CKAMP-44 (von Engelhardt et al., 2010) . Relevant to this review, a recent drug discovery program has identified tool compounds that selectively target AMPARs containing stargazin, CNIH-3, and GSG1-L (Azumaya et al., 2017) . Because the auxiliary proteins occur in variable combinations and stoichiometries in AMPARs in discrete brain regions (Schwenk et al., 2012) , they provide a rich substrate for targeted drug discovery analogous to the g-8 modulator. Although TARPs and CNIH-2 enhance it, GSG1-L and CKAMP44 blunt AMPAR opening, so that selective modulators may allow bidirectional tuning of synaptic transmission in diseased circuits.
Opportunities for Selective Targeting of NMDA and Kainate-Type Glutamate Receptors
Although the AMPAR antagonist perampanel was only recently approved, several medicines targeting NMDA receptors, the other major glutamate-gated ion channel, have been used clinically for decades. Ketamine and memantine are approved for anesthesia (Corssen et al., 1968) and for symptomatic treatment of Alzheimer's disease (Lipton, 2004) , respectively. Recent studies also suggest that ketamine can rapidly and robustly provide benefit in treatment-resistant depression (Abdallah et al., 2015) . Ketamine and memantine are both open channel blockers of the NMDA channel and lack selectivity for specific brain regions. One strategy to improve selectivity would target specific NMDA receptor subunits, and a blocker of NR2B-containing receptors was efficacious in treating depression (Preskorn et al., 2008) . Because direct blockers of NMDA receptors are associated with unwanted side effects, development of nextgeneration agents may benefit from targeting NMDA receptorassociated proteins.
Using the yeast two-hybrid system, a large number of proteins were found to bind the large cytoplasmic C-terminal tail of NMDA receptors (Sheng and Sala, 2001) . Interaction with the postsynaptic density protein PSD-95 anchors NMDA receptors to the cytoskeleton and links the receptors to downstream signaling cascades, including nitric oxide synthase (Brenman et al., 1996) . A peptide inhibitor of binding to PSD-95, NA-1, uncouples NMDA receptors from downstream neurotoxic signaling without affecting channel gating. NA-1 blocks cell death after stroke in several preclinical species, including non-human primates (Cook et al., 2012) . Ongoing clinical studies will determine whether NA-1 may improve outcomes in patients suffering a stroke. Auxiliary subunits of NMDA receptors have not yet been discovered. Because of their great importance, NMDA receptors are being interrogated intensively using strategies outlined in Figure 1 , and one might expect that auxiliary subunits will soon emerge.
Kainate-type glutamate-gated channels also provide attractive drug targets (Contractor et al., 2011) . Like AMPA and NMDA receptors, they are heterotetramers and comprise subunits GluK1-5. For many years, it has been known that central or peripheral injection of kainate itself causes seizures resembling those found in temporal lobe epilepsy, the most common human epilepsy (Cré pel and Mulle, 2015) . High levels of GluK1 in peripheral and central nociceptive pathways underscore a role for kainate receptors in pathological pain (Bhangoo and Swanson, 2013) . Human genetics have established links of GRIK2-4 in schizophrenia, depression, and autism (Contractor et al., 2011) . These data highlight opportunities for kainate receptor antagonists in diverse neuropsychiatric disorders. However, a defect in GRIK2 is associated with mental retardation (Motazacker et al., 2007) , suggesting that general blockage of receptors containing this subunit may be detrimental.
Auxiliary subunits for kainate receptors were anticipated by electrophysiological studies showing fundamentally different gating properties recorded from these receptors at hippocampal synapses versus recombinant cell lines. That is, kainate receptors at the mossy fiber-CA3 synapse mediate prolonged synaptic currents because of very slow deactivation (Castillo et al., 1997) . By contrast, recombinant expression of GluK subunits creates channels with rapid kinetics. This discrepancy motivated biochemical isolation of hippocampal kainate receptors, which were found to contain a Neto-1 or 2 auxiliary subunit (Zhang et al., 2009 ). Interestingly, Neto-1 and 2 both contain complement C1r/C1s, UEGF, BMP1 (CUB) domains similar to that in worm SOL-1 (Zhang et al., 2009) . Importantly, when co-transfected with kainate receptors in cell lines, Neto-1 profoundly slows the gating of kainate receptors to more closely resemble those in neurons (Straub et al., 2011; Tomita and Castillo, 2012) . Furthermore, mossy fiber-CA3 excitatory postsynaptic currents (EPSCs) in Neto-1 knockout mice are accelerated, which demonstrates a physiological role for Neto-1 at this synapse (Tomita and Castillo, 2012) . Because mossy fibers sprout in patients with temporal lobe epilepsy, a Neto-1-specific antagonist represents an attractive drug target that could afford a targeted treatment for epilepsy. Whether Neto-1/GluK receptors can be selectively drugged, as has been achieved for g-8-containing AMPARs, remains uncertain.
GABA A Receptor-Associated Proteins and Neuropharmacology
The major inhibitory receptor in brain, the ionotropic class of GABA receptors (GABA A ), comprises hetero-pentamers formed from combinations of 19 subunits (a1-6, b1-3, g1-3, r1-3, d, ε, p, and q) (Macdonald and Olsen, 1994; Olsen and Tobin, 1990) . The major synaptic GABA A receptors in the brain contain two a, two b, and one g subunit; d-containing subtypes mainly localize at extra-synaptic sites (Belelli et al., 2009) . Dysfunction of GABA A receptors disrupts the inhibitory-excitatory balance and contributes to a broad range of brain disorders, including epilepsy, anxiety, schizophrenia, and depression (Brickley and Mody, 2012) . GABA A receptors have a well-known and rich pharmacology. The ion channel has up to ten distinct binding sites for a broad range of ligands, such as barbiturates, benzodiazepines, volatile anesthetics, and ethanol. This pharmacology has been extensively reviewed (Chua and Chebib, 2017) .
Subunit-specific modulation of GABA A receptors can provide a powerful means for targeting therapy. Benzodiazepine-type drugs bind to an allosteric site at certain extracellular a/g subunit interfaces and activate channels containing a1, a2, a3, and a5 subunits (Chua and Chebib, 2017) . Elegant chemo-transgenic animal studies established that benzodiazepine actions on a1-containing receptors confer sedation, whereas actions on a2-and a3-containing receptors mediate anxiolysis (Rudolph et al., 2001 ). Zolpidem and other ''Z drug''-type treatments for insomnia preferentially enhance a1-containing GABA A receptors. Positive allosteric modulators of a2-and a3-containing receptors have been pursued as non-sedating anxiolytics; the reader is referred to previous reviews (Atack, 2011; Rudolph et al., 2001) . Most recently, an intravenous formulation of allopregnanolone, a positive allosteric modulator of synaptic and extrasynaptic GABA A receptors, showed robust efficacy in post-partum depression (Kanes et al., 2017) . This fits with long-standing evidence that the post-delivery fall in endogenous allopregnanolone contributes to post-partum depression.
GABA A Receptor-Associated Proteins
The complex subunit composition and specific subcellular distribution of GABA A receptors are regulated through an array of protein interactions. The postsynaptic scaffolding protein gephyrin, which co-purifies with glycine receptors, also interacts with the second intracellular loop of the GABA A a2 subunit (Tretter et al., 2008) . Genetic deletion of gephyrin profoundly disrupts GABA A receptor clustering at the synapse but does not ablate extrasynaptic GABA A receptors (Kneussel et al., 1999) . Interestingly, gephyrin mutants show a deficit of a2-but not a1-containing receptors (Tyagarajan and Fritschy, 2014) , suggesting that drugs targeting gephyrin might not influence somnolence, which is associated with a1 receptors. In this vein, Maric et al. (2017) designed peptides that potently disturb the interaction between GABA A receptor and gephyrin to blunt both receptor clustering and inhibitory neurotransmission. In unrelated studies, phenotypic screening of pancreatic b cells with a chemical library identified artemisinins as agents that enhance insulin secretion. Deconvoluting the molecular site of action showed that these drugs stabilize gephyrin in b cells and that their effects on insulin secretion require b cell GABA A receptors (Li et al., 2017) . Whether artemisinins stabilize gephyrin in neurons remains unknown.
Directly targeting gephyrin will likely affect both GABA A and glycine receptors. This may adversely influence respiration and other vital functions because glycine receptors mediate inhibitory transmission in the spinal cord. Brain-specific GABA A receptor complexes would seem to be preferable drug targets. In the brain, postsynaptic GABA A receptors also require the cell adhesion protein neuroligin-2 and the neuron-specific Rho-guanine nucleotide exchange factor (GEF) collybistin, which associate with gephyrin (Papadopoulos et al., 2007) . Most recently, Yamasaki et al. (2017) used proteomics methods to identify GARLH family proteins as stoichiometric components of many brain GABA A receptors. The four-pass transmembrane protein GARLH bridges GABA A receptors and neuroligin-2 and mediates the synaptic clustering and function of GABA A receptors. This emerging structure of GABA A receptor complexes provides abundant new avenues for targeted drug discovery.
Neuropharmacology of nAChR
Neuronal nAChRs provide another family of multimeric ion channels with great pharmaceutical importance (Dineley et al., 2015) . nAChRs comprise five homologous principal subunits that contain four transmembrane domains. These subunits include nine a (a2-10) and three b (b2-4) subunits that show discrete distributions in populations of neurons, glia, and immune cells (Le Novè re et al., 2002) . Through activation of nAChRs, ACh is involved in higher brain functions, including cognition (Rezvani and Levin, 2001 ) and reward-related behaviors (Changeux, 2010) . These receptors also mediate the addictive properties of nicotine. Both Alzheimer's disease (AD) and Parkinson's disease (PD) are associated with loss of nAChRs, and inhibitors of ACh esterase improve cognitive function in AD (Picciotto and Zoli, 2008) The pharmaceutical study of nAChRs has been hampered by the inability to functionally express many nAChRs in recombinant cell lines. Assembly of nAChR is an inefficient process in which only a small percentage of subunits form functional pentamers at the cell surface (Millar and Harkness, 2008) . Improperly folded and un-assembled subunits undergo ER-associated degradation (Figure 4) . Thus, stabilization of un-assembled subunits or blocking the degradation of un-assembled nAChR subunits increases the pool of assembled nAChRs that reach the plasma membrane. The ultrabithorax (UBX)-containing protein UBXN2A can increase surface expression of specific nAChRs by interfering with subunit ubiquitination and proteasomal degradation (Rezvani et al., 2009) . Chronic nicotine treatment increases surface expression of various nAChRs throughout the brain, acting as a pharmacological chaperone to stabilize nAChRs in the ER and promote assembly and trafficking of nAChRs to the plasma membrane (Srinivasan et al., 2014) .
We recently discovered NACHO, a neuronal ER-resident protein (Figure 4 ) essential for the expression of brain a7 nAChRs (Gu et al., 2016) . Co-expression of NACHO with nAChRs enables functional expression of a7 and a3b2 nAChRs and increases expression of a4b2 and a3b4 in HEK293 cells (Gu et al., 2016; Matta et al., 2017) . NACHO knockout mice completely lack expression of functional a7 nAChRs and have reduced levels of other nAChRs throughout the brain. Selectively enhancing neuronal mechanisms involved in expression of nAChRs, such as NACHO and pharmacological chaperones, may provide therapeutic avenues for PD and AD, where loss of nAChRs has been reported.
nAChR Accessory Subunits
The two major nAChR types in the brain are homopentameric a7 receptors and heteropentameric a4b2 receptors, and these likely mediate the positive cognitive effects of nicotine (Levin et al., 2006) . For homopentameric a7, ACh (or nicotine) binds at the five interfaces between subunits ( Figure 5 ). Heteromeric nAChRs contain two conventional agonist binding sites at interfaces between the two pairs of a and b ''structural'' subunits ( Figure 5 ). The fifth subunit, which cannot participate in conventional agonist binding, is referred to as an ''accessory'' (Kuryatov et al., 2008) . Recently, a third ACh-binding site has been described as an unorthodox site at specific interfaces of this fifth accessory subunit ( Figure 5 ) for certain nAChR subtypes (Wang and Lindstrom, 2017) . These unorthodox sites have been described at the interface between a4/a4, a5/a4, and b3/a4. Binding of ACh to these sites alone cannot activate nAChRs but, instead, promotes activation of nAChRs by increasing ACh efficacy (Wang and Lindstrom, 2017) . Thus, these interfaces may allow the development of unique modulators targeting nAChRs with subtype selectivity (Wang and Lindstrom, 2017) .
The b3 and a5 subunits function only as accessories in the fifth subunit position. Incorporation of the a5 subunit into a4b2-, a3b2-, and a3b4-containing nAChRs changes their biophysical and pharmacological properties (Ramirez-Latorre et al., 1996; Wang et al., 1996) . The b3 subunit increases the expression and stability of a6-containing nAChRs (Tumkosit et al., 2006) . The brain region expression pattern of these subunits, along with their association with brain disorders (see below), makes these attractive targets for drug discovery.
Cigarette smoking is far more common in schizophrenia patients than in the general population (Dalack et al., 1998) . A SNP in the a5 subunit-encoding gene (rs16969969) is associated with both schizophrenia and nicotine dependence (Bierut et al., 2008; Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014) . This SNP results in substitution of aspartic acid at residue 398 with asparagine (D398N) in the a5 subunit, which leads to partial loss of a5 function (Bierut et al., 2008) . Also, a5 nAChR knockout mice are insensitive to the aversive effects of high concentrations of nicotine and increase self-administration (Fowler et al., 2011) .
A recent study reported a key role for a5 in prefrontal cortex (PFC) circuitry and that the a5 disease-associated SNP causes schizophrenia-related symptoms in mice. In the PFC, a5 nAChR subunits are selectively expressed by vasoactive intestinal polypeptide (VIP) interneurons (Koukouli et al., 2017 ) that inhibit Unassembled nAChRs are susceptible to ER associated degradation (ERAD.) This process involves translocation from the ER, ubiquitination, and proteasomal degradation. NACHO, RIC-3, and nicotine act as chaperones in the ER to promote assembly of nAChRs, which are then trafficked to the cell surface. Lynx proteins associate with nAChRs to influence trafficking from the ER and modulate gating of nAChRs at the cell surface.
somatostatin (SOM) interneurons, which, in turn, inhibit pyramidal cells. Thus, by inhibiting SOM interneurons, VIP interneurons increase pyramidal cell activity. The a5 SNP therefore reduces activity in VIP interneurons and pyramidal cells, which may explain the PFC hypoactivity in patients and schizophrenia-related phenotypes in these mice (Koukouli et al., 2017) . In addition, the a5 nAChR subunit enhances nicotinic receptor function in PFC layer VI pyramidal neurons (Bailey et al., 2010) , a process involved in attention gating (Proulx et al., 2014) . Consistent with the role of a5-containing nAChRs in cognition, a5 nAChR subunit knockout mice show attention deficits (Bailey et al., 2010) . Thus, increasing a5-containing nAChR function may be a strategy to treat the cognitive impairments observed in various psychiatric and neurological disorders.
The b3 nAChR subunit functions as an accessory subunit in most a6-containing nAChRs (Champtiaux et al., 2003) , and these subunits show similar restricted distributions in discrete brain regions. Both a6 and b3 are prominently expressed on nerve terminals from aminergic neurons (Champtiaux et al., 2003; Gotti et al., 2005) , and nAChRs containing these subunits contribute to nicotine-evoked release of dopamine in the striatum (Azam and McIntosh, 2005) and nucleus accumbens (Exley et al., 2008) . Consistent with their role in regulating mesolimbic dopamine release, a6 knockout mice show deficits in nicotine place preference and are insensitive to cocaine place preference (Sanjakdar et al., 2015) . Thus, a6-containing nAChRs are attractive targets for disorders associated with the mesolimbic dopamine reward system, such as major depression (Chaudhury et al., 2013) . Unfortunately, drug discovery efforts have been hampered because of the inability to functionally express human a6-containing nAChRs in heterologous systems (Gerzanich et al., 1997) . Targeting the b3 accessory subunit may provide a surrogate to access native a6-containing receptors for selective psychopharmacology.
Lynx Proteins
Lynx proteins belong to the lymphocyte antigen-6 (LY6) prototoxin family, characterized by a three-finger fold and disulfide bonds, structurally similar to the a-neurotoxins of snake venom. Similar to a-neurotoxins, lynx proteins interact with nAChRs near their LBD (Lyukmanova et al., 2011) . The first discovered member, Lynx1, negatively modulates nAChR function (Miwa et al., 1999) . Co-expression of Lynx1 with a4b2 shifts receptors toward a high conductance state, increases the rate and extent of desensitization, and lowers the potency of ACh (Ibañ ez-Tallon et al., 2002) . Although these effects were first attributed to allosteric modulation of a4b2 by Lynx1 at the plasma membrane, more recently it was reported that Lynx interacts with a4b2 nAChRs in the ER to stabilize a4a4 dimers, shifting the stoichiometry toward the (a4b2) 2 a4, in which the a4 subunit is in the fifth accessory subunit position (Nichols et al., 2014) . Interestingly, the regulatory role of Lynx1 for a3b4-containing receptors depends on the stoichiometry of the pentamer; Lynx1 affects trafficking of (a3b4) 2 b4 receptors and modulates the function of (a3b4) 2 a3 receptors (George et al., 2017) . Genetic deletion of Lynx1 leads to higher nicotine sensitivity, better performance in certain cognitive tasks, and enhanced susceptibility to neurodegeneration, consistent with hyperactivation of nAChRs in knockout mice (Miwa et al., 2006) . Lynx2 suppresses surface expression of a4b2 and a7 nAChRs Wu et al., 2015) , increases the rate and extent of a4b2 receptor desensitization, and reduces the ACh potency at a4b2 receptors (Tekinay et al., 2009) . Lynx2 is expressed in brain regions associated with mood and anxiety, including the PFC, hippocampus, mediodorsal thalamus, and amygdala. Interestingly, Lynx2 knockout mice show elevated anxiety-related behaviors, likely because of hyperactivation of nAChRs in these brain areas (Tekinay et al., 2009) . Other Lynx proteins expressed in the brain include Ly6h, Lypd6, and Ly6g6e. Ly6h decreases surface expression of a7 nAChRs , and Lypd6 interacts with several nAChR subtypes in the human brain and attenuates nicotine-evoked currents in hippocampal neurons (Arvaniti et al., 2016) . Unlike the other Lynx proteins mentioned above, which tend to inhibit nAChR function or expression, Ly6g6e enhances a4b2 currents and slows desensitization at the cell surface without affecting surface expression .
Several aspects of Lynx proteins make these potential drug targets for psychiatric disorders. The phenotypes of Lynx knockout mice are consistent with Lynx proteins acting as molecular brakes on nAChR function, limiting plasticity after critical periods (Morishita et al., 2010) , limiting memory and neurodegeneration (Miwa et al., 2006) , and limiting anxiety-related behaviors (Tekinay et al., 2009 ). The modulatory effects of Lynx proteins on nAChR function depend on the subunit subtype and stoichiometry of nAChRs. Targeting a selective Lynx protein may also selectively target nAChR subtypes. Differential brain distribution of Lynx proteins enables selective targeting of brain regions associated with certain psychiatric disorders. Inhibition of Lynx protein function may increase nAChR activation at optimal levels, where it may be therapeutic for patients with cognitive deficits, while preventing overstimulation of nAChRs and neuronal degeneration from excess cholinergic excitation (Miwa et al., 2012) . Future development of small molecules that interact with nAChR-Lynx protein complexes could lead to allosteric modulation and enhancement of nAChR function or expression in a Lynx-dependent manner.
Conclusion and Future Opportunities
As elaborated above, targeting protein complexes offers many advantages relative to directly blocking receptors. First, this mechanism provides a diversity of binding pockets that are not limited to the orthosteric sites targeted by traditional pharmaceutical agents. These sites are typically (but not always) allosteric and, therefore, not competitive with endogenous ligands. Blocking allosteric binding sites typically does not cause receptor internalization and homeostatic regulation (Changeux and Christopoulos, 2016; Foster and Conn, 2017) . Also, by modulating rather than fully blocking a receptor, there may be a greater margin of safety (Changeux and Christopoulos, 2016; Foster and Conn, 2017) . As exemplified by the TARP g-8 modulator, targeting receptor-associated proteins can afford brain region selectivity. Because receptors often occur in distinct protein complexes in various cells and tissues, targeting unique components can modulate signaling in specific pathways. This can become especially important in neuropsychiatry, where neurobiological processes are often differentially and sometimes oppositely perturbed in distinct brain regions (Russo and Nestler, 2013) .
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Figure 5. nAChR Stoichiometry and Ligand Binding
Homomeric nAChRs contain 5 binding sites for ACh (blue triangles) at the interphase between each a7 subunit. Heteromeric nAChRs contain 2 primary binding sites for ACh (blue triangles) at the interphase between a and b subunits (orthodox binding sites) and a third unorthodox binding site for ACh (green triangle) between the fifth accessory subunit (shaded) and an a subunit. The b3 and a5 nAChR subunits can only incorporate into the fifth accessory subunit and contain unorthodox binding sites. Potential allosteric modulators at b3 and a5 nAChR subunits (red circle) may present opportunities to selectively target nAChRs containing these subunits.
